

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UMP HEALTHCARE HOLDINGS LIMITED

聯合醫務集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 722)

(1) RE-DESIGNATION OF DIRECTOR; AND (2) CHANGE OF AUTHORISED REPRESENTATIVE

The Board hereby announces that the following changes will take effect from 24 November 2023:

1. Dr. LEE Kar Chung, Felix will be re-designated from executive Director to non-executive Director;
2. Dr. LEE Kar Chung, Felix will cease to act as the Part 16 Authorised Representative and Exchange Authorised Representative; and
3. Ms. KWOK Cheuk Kwan, Jacquen will be appointed as the Part 16 Authorised Representative and Exchange Authorised Representative.

The board (the “**Board**”) of directors (the “**Director(s)**”) of UMP Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that:

RE-DESIGNATION OF DIRECTOR

Dr. LEE Kar Chung, Felix (“**Dr. LEE**”), an executive Director will be re-designated as a non-executive Director with effect from 24 November 2023.

Dr. LEE, aged 42, is currently a Senior Vice President of Chow Tai Fook Enterprises Limited (“CTFE”) with responsibilities in making investments in the healthcare sector in Asia and globally and a director of Healthcare Ventures Holdings Limited, a wholly owned subsidiary of CTFE, a substantial shareholder of the Company. Dr. LEE is also an independent non-executive director of Asymchem Laboratories (Tianjin) Co., Ltd (stock code: 002821.SZ and 6821.HK) and a non-executive director of ClouDr Group Limited (stock code: 9955. HK). Dr. LEE is also a director of various companies of the Group. He has nearly 20 years of experience in healthcare, law and finance. He was an associate with the law firm Freshfields Bruckhaus Deringer before he left in February 2008 to join UBS AG, Hong Kong branch as an analyst in the investment banking department until January 2009. He then joined the investment banking department of Deutsche Bank AG, Hong Kong branch and last held the position of director in the Corporate Advisory Group, where he worked from January 2009 to August 2014. From August 2015 to June 2023, Dr. LEE was an independent non-executive director of China Resources Medical Holdings Company Limited (stock code: 1515.HK), a substantial shareholder of the Company. Dr. LEE is also a Vice Chairman of the China Committee, the Hong Kong General Chamber of Commerce.

Dr. LEE obtained a Bachelor of Laws degree from the London School of Economics and Political Sciences and a Postgraduate Certificate in Laws from the University of Hong Kong in July 2003 and June 2004, respectively. He obtained a Doctor of Business Administration from the University of Wales Trinity Saint David in 2023. He is a solicitor of the High Court of Hong Kong since September 2007 and a solicitor (non-practising) in the Senior Courts of England and Wales since February 2013.

Following his re-designation, Dr. LEE will enter into a new letter of appointment with the Company as a non-executive Director for a fixed term of one year commencing from the date of his re-designation subject to retirement by rotation in accordance with the articles of association of the Company. Under the terms of such appointment letter, the director’s fee payable to Dr. LEE is fixed at the rate of HK\$240,000 per annum. The said director’s fee was determined with reference to his duties and responsibilities and will be subject to review by the remuneration committee of the Company on an annual basis.

As at the date of this announcement, Dr. LEE is beneficially interested in 11,388,000 shares of the Company, representing approximately 1.4% of the issued share capital of the Company. He is also interested in (i) 1,500,000 underlying Shares granted to him by the Company under the Post-IPO Share Option Scheme on 6 November 2018; and (ii) 1,000,000 underlying Shares granted to him by the Company under the Post-IPO Share Option Scheme on 26 May 2021.

Save as disclosed above, as at the date of this announcement, Dr. LEE does not (i) have any relationship with any Directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong); (iii) hold any other position with the Company and any of its subsidiaries; and (iv) hold any directorship in any listed companies in Hong Kong or overseas in the last three years or other major appointments and professional qualifications.

Save as disclosed above, there are no other matters concerning the re-designation of Dr. LEE that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to the requirements of Rule 13.51(2) (h) to (v) of the Listing Rules.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board hereby announces that Dr. LEE Kar Chung, Felix will cease to act as the authorised representative of the Company for accepting service of process or notice in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Part 16 Authorised Representative**”) and the authorised representative of the Company under Rule 3.05 of the Listing Rules (the “**Exchange Authorised Representative**”) all with effect from 24 November 2023.

Accordingly, Ms. KWOK Cheuk Kwan, Jacquen will be appointed as the Exchange Authorised Representative and the Part 16 Authorised Representative all with effect from 24 November 2023.

By Order of the Board
UMP Healthcare Holdings Limited
SUN Yiu Kwong
Chairman

Hong Kong, 21 September 2023

As at the date of this announcement, the Executive Directors of the Company are Dr. SUN Yiu Kwong (Chairman), Dr. SUN Man Kin, Michael (Vice Chairman and Co-Chief Executive Officer), Ms. KWOK Cheuk Kwan, Jacquen (Co-Chief Executive Officer), Mr. TSANG On Yip, Patrick, Dr. LEE Pak Cheung, Patrick and Dr. LEE Kar Chung, Felix; and the Independent Non-executive Directors are Mr. LEE Luen Wai, John, Dr. LI Kwok Tung, Donald, Mr. YEUNG Wing Sun, Mike and Mr. CHAU, Chit Jeremy.